Clinical Trial Update: Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two secukinumab regimens in patients weighing 90 kg or more with moderate to severe chronic plaque psoriasis; study completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Chronic Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-07